2Chemotherapy of metastatic colorectal cancer [ J ]. Prescrire Int, 2010,19(109) :219 -224.
3Muro K,Nippon Rinsho. Transition of chemotherapy for metastatic colorectal cancer and recent advances[ J]. Nippon Rinsho,2010,68 (6):1143 -1149.
4George P,Kim,Daniel J. Sargent phaseⅢnoninferiority trial com- paring irinotecan with oxaliplatin, fluorouracil, and leucovorin in pa- tients with advanced colorectal carcinoma previously treated with flu- orouraeil : N9841 [ J]. J Clin Oneo1,2009,27 ( 17 ) :2848 - 2854.
5Cartwright T, McCollum D, Boehm KA. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/ or locally advanced colorectal cancer[ J]. Am J Clin Oncol,2010, 33(3) :307 -313.
6Garcia-Alfonso P,Munoz-Martin A,Mendez-Urena M,et al. Capecit- abine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first - line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group[ J]. Br J Cancer,2009,101 (7) : 1039 - 1043.
7Muro K,Boku N, Shimada Y, et al. lrinotecan plus S - 1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer:a random- ised phase 2/3 non-inferiority study ( F1R1S study) [ J]. Lancet On- col,2010,11 (9) :853 -860.
8Hsiao SC,Lin JF,Chuang MT,et ak Retrospectively comparative e- valuation of the first-and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer [ J ]. Int Surg, 2009,94 ( 4 ) :298 - 303.
9Sheikh HY, Valle JW, Waddell T,t al. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer [ J ]. British Journal of Cancer,2008,99:577 - 583.
10Bokemeyer C,Bondarenko I. FluorouraciI,Ieuco,Jorin, and oxahpla- tin with and without cetuximab in the first-line treatment of metastat- ic colorectal cancer [ J ]. J Clin 0ncol,2009,27 : 663 - 671.
4Wong N S. Fernando N H. Bendell J C. et al. A phase II study of oxaliplatin , dose-intense capecitabine , and high-dose bevacizumab in tbe treatment of metastatic colorectal Cancer[J]. Clin Colorectal Cancer, 2011, 10(3) :210-216.
5Cranmer Sargison G,Kundapur V.Park Somers E.et al. Planning target volume margin evaluation and critical structure sparing for rectal cancer patients treated prone on a bellybcard[J] Clin Oncolt R Coli RadioD ,2013.25(3) :e17-e22.
6Kennecke H. Berry S, Wong R. et al. Pre-operative bevacizurnab , capecitabine , oxaliplatin and radiation among patients witb locally advanced or low rectal cancer: a phase II trial[J]. Eur J Cancer,20J2,48(1) :37-45.
7An Xin , Lin Xi, Wang Fenghua , et al, Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal Caneer , a meta analysis[J]. Eur I Cancer,2013,49(4) :843-851.
8Kripp M, Wieneke] ? Kienle P, et al. Intensified neoadjuvant chemoradiotherapy in locally advanced recta! Cancer-impact on long-term quality of Life[J]. Eur] Surg Oncol , 2012, 38 (6) :472-477.
9Mammano E.Galdi F,Pierobon M,et al. Multiplexed protein signal pathway mapping identifies patients with rectal Cancer that responds to neoadjuvant treatment [J]. Clin Colorectal Cancer, 2012 .11( 4) : 268-274.
10Dinu D,Birla R,Caragui A, et al. Therapeutic strategies in colonic cancer[ J ]. Chirurgia (Bucur) ,2014,109 (6) :741 - 746.
